In this review:
Updated results from PACIFIC
Brigatinib vs crizotinib in ALK+ NSCLC
Mortality results from NELSON
Atezolizumab in untreated ES-SCLC
Nintedanib in unresectable MPM
Durvalumab in mesothelioma
Air pollution and lung cancer
PCI for limited-stage SCLC: CONVERT
KEYNOTE-407: pembrolizumab in NSCLC
Poziotinib in EGFR and HER2 exon 20 mutant NSCLC
Please login below to download this issue (PDF)